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Abstract Using the computer docking program EUDOC, in
silico screening of a chemical database for inhibitors of human
adenovirus cysteine proteinase (hAVCP) identified 2,4,5,7-
tetranitro-9-fluorenone that selectively and irreversibly inhibits
hAVCP in a two-step reaction: reversible binding (Ki = 3.09 WM)
followed by irreversible inhibition (ki = 0.006 s31). The reversible
binding is due to molecular complementarity between the
inhibitor and the active site of hAVCP, which confers the
selectivity of the inhibitor. The irreversible inhibition is due to
substitution of a nitro group of the inhibitor by the nearby
Cys122 in the active site of hAVCP. These findings suggest a
new approach to selective, irreversible inhibitors of cysteine
proteinases involved in normal and abnormal physiological
processes ranging from embryogenesis to apoptosis and pathogen
invasions. ß 2001 Published by Elsevier Science B.V. on be-
half of the Federation of European Biochemical Societies.
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1. Introduction
Cysteine proteinases are involved in a wide variety of nor-
mal and abnormal physiological processes ranging from em-
bryogenesis [1] to programmed cell death [2,3] and in viru-
lence or replication of many viruses, bacteria, and parasites
[4]. Human adenovirus cysteine proteinase (hAVCP) is one
such proteinase and is responsible for the production of in-
fectious viral particles [5,6]. Selective inhibitors of hAVCP
could potentially be used as e¡ective antiviral agents. Novel
approaches to selective inhibitors of cysteine proteinases are
therefore highly desirable for developing e¡ective tools to
study functions of cysteine proteinases and therapeutic agents.
Several classic cysteine proteinase inhibitors such as iodo-
acetate, dithiodipyridine, and p-chloromercuribenzoate are ef-
fective in inhibiting hAVCP, however, they are non-selective
and can not be used as antiviral agents [7,8]. Although the X-
ray structure of hAVCP was reported in 1996, to date, no
selective and irreversible inhibitors of hAVCP have been re-
ported despite various reported methods for developing cys-
teine proteinase inhibitors, in particular, those aiming at re-
actions with the nucleophilic cysteine residue in the active site
of drug targets [9,10].
To develop antiviral agents for adenovirus infections [11^
15] and to develop novel approaches to selective inhibitors of
cysteine proteinases, we have performed in silico screening of
a chemical database for inhibitors of hAVCP and identi¢ed
2,4,5,7-tetranitro-9-£uorenone (TNFN, see Fig. 1) as a new
inhibitor lead that selectively and irreversibly inhibited
hAVCP in a two-step reaction. The mechanism of selective
and irreversible inhibition of hAVCP by TNFN proposed in
this report suggests a new approach to selective, irreversible
inhibitors of cysteine proteinases.
2. Materials and methods
2.1. Materials
Tris^HCl, HEPES, and papain were purchased from Sigma (St.
Louis, MO, USA). TNFN was purchased from Pfaltz and Bauer
(Waterbury, CT, USA). Other chemicals were purchased from Aldrich
Chemical (Madison, WI, USA) or synthesized as described below.
pVIc (GVQSLKRRRCF) was obtained from Research Genetics
(Huntsville, AL, USA). The £uorogenic substrates (Leu-Arg-Gly-
Gly-NH)2-Rhodamine for hAVCP and (Phe-Arg-NH)2-Rhodamine
for papain were synthesized and puri¢ed as described previously
[8,16,17].
2.2. Enzymes
Recombinant hAVCP was puri¢ed as described previously [16,18].
hAVCP^pVIc complexes were formed by incubating 100 WM hAVCP
with 150 WM pVIc in 10 mM Tris (pH 7.5), 5 mM NaCl, and 1 mM
EDTA at 4‡C for 16 h.
2.3. In silico screening
The 1998 release of the Available Chemicals Directory obtained
from MDL Information Systems (San Leandro, CA, USA) was
used in the in silico screening. Compounds in the Available Chemicals
Directory that had shape and charge complementarity to the X-ray
structure of the active site in hAVCP [19] were identi¢ed by using a
computer docking program, EUDOC [20], according to a published
protocol [21].
2.4. Enzymatic assays
To characterize the irreversible inhibition of hAVCP^pVIc by
TNFN, a competition was set up between the substrate and the in-
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hibitor for the active site of the enzyme [22]. The results were then
used to calculate the equilibrium dissociation constant for reversible
binding by the inhibitor and a ¢rst-order rate constant for irreversible
inhibition by the inhibitor.
The interaction between hAVCP^pVIc and the substrate can be
characterized by:
E  SHKm EWSÿ!kcat E  P 1
where E is enzyme hAVCP^pVIc; S is the substrate (Leu-Arg-Gly-
Gly-NH)2-Rhodamine; EWS is the adsorptive enzyme^substrate com-
plex; P is the product (Leu-Arg-Gly-Gly-NH)2-rhodamine; Km is the
Michaelis constant; kcat is a ¢rst-order rate constant.
The interaction between hAVCP and the inhibitor can be charac-
terized by:
E  IHK i EWIÿ!ki EI 0 2
where I is the irreversible inhibitor TNFN; EWI is an adsorptive en-
zyme^inhibitor complex; EIP is the irreversibly inhibited enzyme^in-
hibitor complex; Ki is an equilibrium dissociation constant; ki is a
¢rst-order rate constant.
Assays with hAVCP^pVIc complexes contained 10 mM Tris (pH
8.0) and 5 mM octylglucoside. Assays with papain contained 25 mM
NaAc (pH 5.0). Papain was activated just prior to an assay by pre-
paring a 1:50 dilution of a stock solution of 5 mg ml31 in 25 mM
NaAc (pH 5.0) into 50 mM NaAc (pH 5.0) containing 5 mM dithio-
threitol and incubating at 37‡C for 4 min. Assays, usually started with
the addition of enzyme, were performed in an ISS spectro£uorometer
(Urbana, IL, USA) equipped with a 4-position cuvette holder. Fluo-
rescence readings were taken continuously for 40 min. The excitation
wavelength was 492 nm, and the emission wavelength was 523 nm,
both with a 4 nm bandpass ¢lter.
2.5. Determination of Ki and ki
Competition assays between the substrate and TNFN for the active
site of hAVCP^pVIc complexes contained 100 nM hAVCP^pVIc,
3 WM (Leu-Arg-Gly-Gly-NH)2-Rhodamine and 0.3, 0.5, 0.7, 1.0,
2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, and 9.0 WM TNFN. Competition assays
between the substrate and TNFN for the active site of papain con-
tained 8.7 nM papain, 20 WM (Phe-Arg-NH)2-Rhodamine and 2.5,
5.0, 10, 30, 50, 60, 70, 80, and 100 WM TNFN.
2.6. Data analysis
For the experiments to determine Ki and ki, the primary data were
imported into the program TableCurve from Jandel Scienti¢c (San
Rafael, CA, USA) and plotted as amount of product (P) formed
versus time (t). The program determined an equation that best de-
scribed the data points and then, using that equation, drew a best-¢t
curve through the data points.
2.7. Synthesis of 2-methylsulfanyl-4,5,7-trinitro-9-£uorenone
Sodium thiomethoxide (30 mg, 0.43 mmol) was placed in a 25 ml
round bottom £ask that had been purged with nitrogen and equipped
with a stir bar. Anhydrous DMSO (10 ml) was added, followed by
154 mg (0.43 mmol) of 2,4,5,7-tetranitro-9-£uorenone, while main-
taining a constant £ow of nitrogen. The £ask was then sealed with
a septum. Immediately upon addition of the 2,4,5,7-tetranitro-9-£uo-
renone, the solution in the £ask became dark blue in color. After
stirring at 37‡C for 18 h, the DMSO was removed under reduced
pressure. The residue was partitioned between 25 ml of water and
10 ml of CH2Cl2. The aqueous phase (dark red) was extracted with
2U10 ml CH2Cl2. The combined organic phases were dried over
MgSO4 and the solvent was removed on a rotary evaporator. This
crude product was chromatographed using a CombiFlash system
from Isco (Lincoln, NE, USA) equipped with a 20U300 mm column
packed with 35^75 WM Geduran silica gel 60 obtained from EM
Science (Gibbstown, NJ, USA) using a gradient of 0^10% methanol
in chloroform as eluant. The fractions containing product were com-
bined and the solvent was removed using a rotary evaporator to give
98 mg (63%) of product as orange needles. M.P. 222^223‡C (uncor-
rected). Found C, 46.54; H, 2.09; N, 11.39%; C14H7N3O7S requires
C, 46.54; H, 1.95; N, 11.63%. 1H-NMR (600 MHz, DMSO-d6) N 8.86
(d, 1H, J = 1.9 Hz), 8.59 (d, 1H, J = 2.0 Hz), 8.05 (d, 1H, J = 1.6 Hz),
8.02 (d, 1H, J = 1.6 Hz), and 2.72 (s, 3H). 13C-NMR (600 MHz,
DMSO-d6) N 185.8, 148.6, 148.2, 146.1, 144.4, 138.2, 137.7, 137.5,
126.6, 125.8, 125.5, 124.6, 122.1, and 14.4. Assignment of structure
was based upon the 1H-NMR spectral data. Of the two possible
isomers that could be formed by the aromatic nucleophilic substitu-
tion of thiomethoxide for a nitro group in the starting material, only
one isomer would be expected to have similar chemical shifts for Ha
and Hb (Fig. 2).
2.8. Synthesis of bis-(3,5-dinitrophenyl)-methanone
Benzophenone (5.00 g, 27.4 mmol) was added to 25 ml concen-
trated sulfuric acid cooled in an ice water bath. This solution was
added to a solution of 80 ml concentrated sulfuric acid in 35 ml
concentrated nitric acid cooled in an ice water bath. This solution
was warmed to room temperature for 60 min then slowly heated to
90‡C over 75 min. The solution was maintained at 90‡C for 105 min.
After cooling the solution in an ice water bath, it was poured over 600
g of crushed ice. The resulting yellow precipitate was recovered by
vacuum ¢ltration and washed with water, saturated sodium bicarbon-
ate solution and additional water. 1H-NMR indicated a mixture of
nitration products. This solid was dissolved in 25 ml concentrated
sulfuric acid and was added to a solution of 75 ml concentrated
sulfuric acid mixed with 25 ml concentrated nitric acid. This solution
was heated at 140‡C for 60 min then worked up as described above.
Recrystallization from acetone gave 2.03 g (20% yield) of white
needles. M.P. 242^243‡C (uncorrected). Found C, 43.18; H, 1.67;
N, 15.65%; C13H6N4O9 requires C, 43.11; H, 1.67; N, 15.47%.
1H-NMR (600 MHz, DMSO-d6) N 9.09 (t, 2H, J = 2.0 Hz) and 8.84
(d, 4H, J = 2.0 Hz). 13C-NMR (150 MHz, DMSO-d6) N 189.2, 148.2,
138.3, 129.5, and 122.2.
2.9. Synthesis of (3,5-dinitrophenyl)-(3-methylsulfanyl-5-nitrophenyl)-
methanone
Procedure was identical to that for 2-methylsulfanyl-4,5,7-trinitro-
9-£uorenone. Upon addition of the bis-(3,5-dinitrophenyl)-methanone
to the sodium thiomethoxide solution, the reaction mixture turned
dark red. Subsequent work-up gave rise to 47 mg (30%) of the desired
product as yellow needles. M.P. 177^178‡C (uncorrected). Found C,
46.13; H, 2.49; N, 11.44%; C13H6N4O9 requires C, 46.28; H, 2.50;
N, 11.57%. 1H-NMR (500 MHz, DMSO-d6) N 9.07 (t, 1H, J = 2.0 Hz),
8.82 (d, 2H, J = 2.1 Hz), 8.32^8.30 (m, 1H), 8.23^8.21 (m, 1H), 8.02^
8.00 (m, 1H), and 2.64 (s, 3H). 13C-NMR (125 MHz, DMSO-d6) N
190.3, 148.4, 148.2, 142.7, 138.8, 132.0, 129.4, 123.4, 121.8, 120.2, and
14.5.
3. Results and discussion
In order to develop e¡ective antiviral agents, peptides and
Fig. 1. A model reaction of aromatic nucleophilic substitution.
Fig. 2. Chemical structures of methylsulfanyl-substituted TNFN.
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charged molecules were excluded in our in silico screening,
since they were not generally considered to be druggable.
Docking 67 928 neutral, non-peptidic compounds selected
from the Available Chemicals Directory into the active site
of the hAVCP crystal structure [19], the EUDOC program
identi¢ed 30 compounds as inhibitor candidates. The top
three candidates were purchased and tested experimentally.
The top compound, TNFN, e¡ectively inhibited hAVCP,
while the other two were inactive. Kinetics experiments dem-
onstrated that TNFN inhibited hAVCP in a two-step reac-
tion: reversible association with an equilibrium dissociation
constant, Ki, of 3.09 WM followed by irreversible inhibition
with a ¢rst-order rate constant, ki, of 0.006 s31. The irrevers-
ible inhibition was con¢rmed by a dilution experiment. When
hAVCP was incubated with TNFN at the Ki concentration
(3.09 WM), 50% of the enzymatic activity was inhibited. When
the reaction solution was diluted by 10-fold, the degree of
inhibition was still 50%. This indicated that hAVCP was irre-
versibly inhibited and that no dissociation occurred upon di-
lution of the inhibitor^enzyme complex.
To understand the two-step inhibition mechanism at the
atomic level, we examined the most energetically stable
TNFN^hAVCP complex generated by the EUDOC program
and found shape and charge complementarity between TNFN
and the active site of hAVCP (Fig. 3). The complementarity is
indicated by the calculated relative intermolecular interaction
energy of 339.9 kcal/mol that is composed of the steric inter-
action energy of 327.5 kcal/mol and the electrostatic interac-
tion energy of 312.4 kcal/mol. In addition, the 2-substituted
nitro group formed a hydrogen bond with the nitrogen proton
of Gly2 and the carbonyl oxygen atom formed a hydrogen
bond with the hydrogen atom attached to the delta nitrogen
atom of His54 in the hAVCP complex. Furthermore, the nitro
group at position 2 of TNFN was located close to Cys122 in
the active site of hAVCP (Fig. 3A). The distance of carbon 2
in TNFN to the sulfur atom of Cys122 was 5.0 Aî . We hy-
pothesized that the reversible binding was due to the shape
and charge complementarity, and that the irreversible inhibi-
tion was caused by aromatic nucleophilic substitution of the
2-nitro group by the nearby Cys122, namely, the nucleophilic
thiolate added at position 2 of TNFN followed by elimination
of the 2-nitro group.
We accordingly carried out a model reaction of TNFN with
one equivalent of sodium thiomethoxide in dimethylsulfoxide
at 37‡C. This reaction produced 2-methylsulfanyl-4,5,7-trini-
tro£uorenone as the major product in 63% yield (Fig. 1).
NMR spectroscopic analysis revealed that the substitution
did occur at position 2 of TNFN, thus directly supporting
the substitution mechanism for the irreversible binding of
TNFN to hAVCP.
We also docked TNFN into the active site of the X-ray
structure of another cysteine proteinase, papain [23], and
Fig. 3. The EUDOC generated most energetically stable complexes of TNFN^hAVCP (A) and TNFN^papain (B) showing shape complemen-
tarity between TNFN (red) and enzyme active site (green).
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found that the 2-substituted nitro group of TNFN was lo-
cated close to Cys25 in the active site of the most energetically
stable TNFN^papain complex generated by EUDOC (Fig.
3B). The 2-position carbon atom of TNFN was at a distance
of 4.9 Aî from the sulfur atom of Cys25 (Fig. 3B). In contrast
to the binding of TNFN to hAVCP, the 2-substituted nitro
group of TNFN did not form a hydrogen bond with any
residue of papain. The intermolecular interaction energy in
the papain complex is 1 kcal/mol higher than that in the
hAVCP complex. These results could suggest qualitatively
that TNFN would ¢rst bind reversibly to papain but with a
larger equilibrium dissociation constant than it exhibited in
binding to hAVCP, and would then irreversibly inhibit pa-
pain. Kinetic experiments revealed that TNFN irreversibly
inhibited papain in a two-step manner as well : reversible as-
sociation with a larger Ki of 9.24 WM followed by irreversible
inhibition with a slower ki of 0.001 s31, thus further support-
ing the proposed irreversible inhibition mechanism.
To investigate the selectivity of agents that inhibit cysteine
proteinases through the mechanism of the aromatic nucleo-
philic substitution, we synthesized an analog of TNFN, bis-
(3,5-dinitrophenyl)-methanone. This analog di¡ers from
TNFN in that it has a non-planar structure whereas TNFN
has a planar structure (Fig. 4). Consequently, this analog does
not ¢t well into the active site of hAVCP, which has been
con¢rmed by our docking study using the same procedure
as used in docking TNFN. The calculated intermolecular in-
teraction energy of TNFN was 3 kcal/mol lower than that of
the TNFN analog. Experimental study revealed that the ana-
log did not reversibly or irreversibly inhibit hAVCP at con-
centrations up to 5.0 WM (it precipitated at concentrations
greater than 5.0 WM), despite our model reaction revealing
that the nitro group of this analog could be replaced by the
methylsulfanyl group when the analog was treated with one
equivalent of sodium thiomethoxide in dimethylsulfoxide at
37‡C. The results demonstrate that arylnitro-containing com-
pounds can not alkylate the cysteine residue in the active site
of proteins without their shape and charge complementarity
to the active site, thus suggesting that inhibitors designed ac-
cording to the aromatic nucleophilic substitution mechanism
can be selective.
The active site structure of hAVCP is reportedly very sim-
ilar to that of papain as a consequence of convergent evolu-
tion, although the two enzymes have di¡erent substrates [19].
When the central helix containing the active site nucleophile
of papain is aligned with a similar helix in hAVCP, the three
amino acids involved in catalysis in the active site of papain,
Cys25, His159, and Asn175, juxtapose with Cys122, His54,
and Glu71 of hAVCP, respectively [19]. Even the nitrogen
atoms of Gln19 and Cys25 in the oxyanion hole of papain
juxtapose with those of Gln115 and Cys122 in the oxyanion of
hAVCP [19]. Despite the strong similarity in the active site
topology of the two enzymes, TNFN, identi¢ed solely on the
basis of a search using the hAVCP active site, is already an
18-fold more selective irreversible inhibitor of hAVCP accord-
ing to the reported de¢nition of selectivity. This selectivity is
partly due to the fact that the hydrogen bond between the 2-
substituted nitro group of TNFN and hAVCP is disabled in
the papain^TNFN complex as suggested by the docking study
[17]. While assays with other proteinases such as chymotryp-
sin and cysteine-containing non-proteinases such as gluta-
thione would be appropriate to further evaluate the selectivity
of TNFN, the present study does suggest that further struc-
tural modi¢cation of TNFN according to active sites of
hAVCP and papain would lead to analogs that ¢t only the
active site of hAVCP thus inhibiting hAVCP with improved
selectivity.
Cocrystals of the hAVCP^pVIc complex with TNFN have
been obtained which di¡racted at a resolution of 3 Aî . It is
clear that extra density appears in the active site over Cys122,
but at this resolution it is di⁄cult to assign structure to this
density (McGrath and Mangel, unpublished). However, on
the basis of the reaction of TNFN with sodium thiomethoxide
and the kinetics experiments described above, it is conceivable
that e¡ective inhibitors of cysteine proteinases can be devel-
oped by searching for bulky compounds that ¢t only the
active site of the targeted cysteine proteinase and have an
arylnitro group located within 5.0 Aî proximity of the cysteine
residue in the active site of the proteinase. Our recent survey
reveals that 2% of launched drugs in the 2001 release of the
MDL drug database (San Leandro, CA, USA) contain aryl-
nitro groups, indicating that arylnitro groups are not toxic
and the proposal of using such groups in the design of cys-
teine proteinase inhibitors is reasonable.
The advantage of the design of bulky, arylnitro-containing
compounds is 2-fold. First, the inhibitors so developed are
selective because these compounds are designed not to ¢t
the active sites of unrelated enzymes. The chance for these
compounds to react with the active site cysteine of the unre-
lated enzymes is remote because of the low chemical reactivity
of the arylnitro group relative to thiol-containing compounds
and iodoacetate analogs. Second, such inhibitors are irrevers-
ible because they undergo aromatic nucleophilic substitution
due to the ‘neighboring e¡ect’ in chemical kinetics only when
Fig. 4. Ball and stick models of TNFN (top) and bis-(3,5-dinitro-
phenyl)-methanone (bottom) with the non-planar conformation opti-
mized by an ab initio calculation using the HF/6-31G* method.
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they bind at the active site of the targeted enzyme. This ap-
proach is novel in that a much less chemically reactive arylni-
tro group has, for the ¢rst time, been proposed to react with
the active site cysteine residue to achieve irreversible inhibition
instead of using reactive agents such as thiol-containing com-
pounds and iodoacetate analogs [9,10]. The importance of this
nucleophilic substitution method for developing selective and
irreversible cysteine proteinase inhibitors rests on the fact that
most irreversible inhibitors of cysteine proteinases are non-
selective because they are chemically reactive and small in
size [2,4,24]. The common alkylating agents such as iodoace-
tate or N-ethylmaleimide ¢t the active site of any cysteine
proteinase and are thus able to alkylate any cysteine protein-
ase; nitric oxide will nitrosylate the sulfur atom of any cys-
teine residue involved in catalysis for the same reasons.
Although recent studies have demonstrated that S-nitroso-
thiols can mask the catalytic cysteine residue with a large
chemical group via disul¢de bond formation [24^26], these
compounds can not be used as selective inhibitors of cysteine
proteinases, because S-nitrosothiols can inhibit other cysteine
proteinases as nitric oxide, released by homolysis, can react
with any cysteine proteinase.
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